Filing identity and reporting period
Important mismatch: The supplied text is Caladrius Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, filed February 25, 2021. It does not identify Lisata Therapeutics, Inc. or report 2019 Q4. Confirm that this is the intended filing before relying on the summary.
Business context
Caladrius was a clinical-stage biopharmaceutical company developing autologous CD34+ cell therapies. Its principal programs targeted coronary microvascular dysfunction (CLBS16), critical limb ischemia and Buerger’s disease (HONEDRA/CLBS12), chronic kidney disease (CLBS201), and no-option refractory disabling angina (OLOGO/CLBS14). The company had no approved products and had not generated product-sales revenue.
Financial performance and position
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | No product-sales revenue reported | No product-sales revenue reported |
| Research and development expense | $9.3 million | $10.8 million |
| General and administrative expense | $9.9 million | $9.3 million |
| Total operating expenses / operating loss | $19.1 million | $20.1 million |
| Net loss attributable to common shareholders | $8.2 million | $19.4 million |
| Basic and diluted loss per share | $0.53 | $1.88 |
| Cash used in operating activities | $8.8 million | $18.9 million |
At December 31, 2020, cash, cash equivalents and marketable securities totaled $34.6 million, versus $25.2 million a year earlier; working capital was $31.8 million and stockholders’ equity was $32.5 million. Total liabilities were $3.8 million, primarily accounts payable, accrued liabilities and lease obligations. The filing reports no interest paid and does not identify outstanding borrowings in the presented balance sheet.
FY 2020’s net loss included a $10.9 million income-tax benefit from selling New Jersey net operating losses. The company reported $18.6 million of financing cash inflows, largely from equity and warrant offerings and ATM sales. Marketable securities are included in the reported liquidity figures; they should not be added a second time.
Changes versus the prior period
- Net loss narrowed substantially, but this was principally associated with the one-time tax benefit; operating expenses fell 5%, while R&D decreased and G&A increased.
- Operating cash use fell by approximately $10.1 million year over year.
- Equity financing increased: the company reported $18.7 million net proceeds from capital-stock issuance in 2020, compared with $1.3 million in 2019, increasing year-end common shares outstanding from 10.5 million to 19.4 million.
- Cash and marketable securities increased, supported by financing and the tax-loss sale.
Outlook, commentary and risks
- Management stated that year-end cash was expected to fund operating expenses for at least 12 months after the financial statements were issued, assuming an OLOGO Phase 3 trial would not begin without additional funding. The company said additional capital would be needed for longer-term development.
- In February 2021, the company reported $25.0 million gross proceeds from a January private placement and approximately $60.7 million net proceeds from February registered direct offerings, alongside warrants. It also reported $1.8 million net proceeds from subsequent warrant exercises. These are post-year-end events, not FY 2020 operating results.
- HONEDRA enrollment in Japan was delayed by COVID-19 disruptions; management expected enrollment completion in Q2 2021. CLBS16’s 105-patient Phase 2b FREEDOM study began enrollment in December 2020. CLBS201’s Phase 2 study was being considered for the second half of 2021. Discussions with the FDA on OLOGO’s proposed Phase 3 size and scope continued; the filing cites an earlier estimate of approximately $70 million in external expenses for the previously discussed trial.
- Key risks include ongoing losses and dependence on further financing; clinical, regulatory and enrollment uncertainty; COVID-19 disruption; autologous-cell manufacturing variability and reliance on third-party manufacturers without qualified backup suppliers; and possible dilution from equity offerings and warrants. Product candidates had not received marketing approval.
- The company reported no legal proceedings expected to have a material effect, no off-balance-sheet arrangements, and no critical audit matters. The auditor gave an unqualified opinion on the financial statements; management assessed internal control over financial reporting as effective. The auditor did not express an opinion on internal-control effectiveness.
Important facts for investors to verify
- Whether the intended issuer and period are Caladrius Biosciences and FY 2020, rather than Lisata Therapeutics and 2019 Q4.
- The distinction between the $8.2 million FY 2020 attributable net loss and the $10.9 million one-time tax benefit from the New Jersey NOL sale.
- Current cash, cash runway and any subsequent spending or financing after the February 2021 offerings.
- The terms, share issuance and potential dilution from the January and February 2021 offerings, warrants and warrant exercises. The cover reports 59,505,261 shares outstanding as of February 25, 2021; reconcile this with the year-end count and subsequent issuance disclosures.
- Clinical-trial enrollment, regulatory discussions, manufacturing capacity, and any updates to the cited OLOGO Phase 3 cost estimate.